Purpose

To avoid harm resulting from delayed administration of adrenaline to patients with anaphylaxis who have their own adrenaline injector and could self-medicate safely during a healthcare encounter or admission.

Purpose

To reduce adverse outcomes during or after anaphylaxis due to low blood pressure. Fatality can occur within minutes if a patient stands or sits up suddenly while they have inadequate perfusion.

Purpose

To ensure immediate treatment with intramuscular adrenaline as soon as anaphylaxis is recognised or suspected and prevent progression to life-threatening symptoms.

Purpose

To improve the time to optimal diagnosis and treatment for people with anaphylaxis.

Quality statements

The Acute Anaphylaxis Clinical Care Standard includes six quality statements. By describing what each statement means, the standard supports:

The quality statements in the Acute Anaphylaxis Clinical Care Standard describe the expected standard for key components of patient care.

What do clinicians need to know?

The Commission, in collaboration with the Therapeutic Goods Administration (TGA) and the Australian Government Department of Health is undertaking a project to develop and pilot the Australian Unique Device Identifier Framework (UDI Framework) for Australian health service organisations (UDI4H).

Overview

In 2020 the Australian Government Department of Health (the Department) engaged the Commission to develop minimum information requirements for a PBS eCMC to support safe prescribing, administration, dispensing and claiming of PBS and non-PBS chemotherapy medicines.